{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:40:04Z","timestamp":1789584004521,"version":"build-2803163510"},"reference-count":61,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BLCTT"],"DOI":"10.2147\/blctt.s309171","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T13:55:14Z","timestamp":1678197314000},"page":"1-12","source":"Crossref","is-referenced-by-count":23,"title":["PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise"],"prefix":"10.2147","volume":"Volume 13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7446-894X","authenticated-orcid":true,"given":"Naji","family":"Bou Zeid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5113-8681","authenticated-orcid":true,"given":"Victor","family":"Yazbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrclinonc.2013.10","volume":"10","author":"Rodon","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s11912-011-0187-7","volume":"13","author":"Schatz","year":"2011","journal-title":"Curr Oncol Rep"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3960\/jslrt.20036","volume":"60","author":"Kikushige","year":"2020","journal-title":"J Clin Exp Hematop"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1056\/NEJMra1908213","volume":"383","author":"Burger","year":"2020","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","volume":"391","author":"Hallek","year":"2018","journal-title":"The Lancet"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1310\/hpj5203-187","volume":"52","author":"Barnett","year":"2017","journal-title":"Hosp Pharm"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1182\/blood-2014-07-586826","volume":"124","author":"Dreger","year":"2014","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.19.03355","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","volume":"390","author":"Armitage","year":"2017","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1080\/14656566.2019.1582643","volume":"20","author":"Al Juhaishi","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/17474086.2017.1318053","volume":"10","author":"Jiang","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ajh.25696","volume":"95","author":"Freedman","year":"2020","journal-title":"Am J Hematol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/blood.2020010263","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11864-019-0687-5","volume":"20","author":"Sindel","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1182\/blood.2019001088","volume":"134","author":"Luminari","year":"2019","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/17474086.2017.1303374","volume":"10","author":"Leslie","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"ra60","DOI":"10.1126\/scisignal.2001104","volume":"3","author":"Ramadani","year":"2010","journal-title":"Sci Signal"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1126\/science.1073560","volume":"297","author":"Okkenhaug","year":"2002","journal-title":"Science"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3390\/cancers14061571","volume":"14","author":"Hus","year":"2022","journal-title":"Cancers"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1126\/science.7684160","volume":"260","author":"Tuveson David","year":"1993","journal-title":"Science"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.00891.x","author":"Kong","year":"2008","journal-title":"Cancer Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/s41598-018-19460-5","volume":"8","author":"Abdelrasoul","year":"2018","journal-title":"Sci Rep"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.tibs.2005.02.008","volume":"30","author":"Vanhaesebroeck","year":"2005","journal-title":"Trends Biochem Sci"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cell.2009.08.041","volume":"139","author":"Srinivasan","year":"2009","journal-title":"Cell"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.clml.2014.01.007","volume":"14","author":"Westin","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s10875-014-0012-9","volume":"34","author":"Crank","year":"2014","journal-title":"J Clin Immunol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.1158\/1078-0432.CCR-05-0637","volume":"11","author":"Gulmann","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/j.1365-2141.2010.08123.x","volume":"149","author":"Hasselblom","year":"2010","journal-title":"Br J Haematol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/2050-7771-1-30","volume":"1","author":"Fang","year":"2013","journal-title":"Biomark Res"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1080\/13543784.2017.1384815","volume":"26","author":"Lampson","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1200\/JCO.19.00215","volume":"37","author":"Fruman","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","volume":"20","author":"Vanhaesebroeck","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(22)00200-5","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"key":"ref35","unstructured":"FDA. Research C for DE and. FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib). FDA; 2022. Availabe from: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-investigating-possible-increased-risk-death-lymphoma-medicine-ukoniq-umbralisib. Accessed June 8, 2022."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s40265-014-0285-6","volume":"74","author":"Markham","year":"2014","journal-title":"Drugs"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s40265-017-0838-6","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s40265-018-1013-4","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s40265-021-01504-2","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1182\/blood-2014-07-587279","volume":"124","author":"Dong","year":"2014","journal-title":"Blood"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1200\/JCO.18.00915","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"ref46","unstructured":"Meeting of the Oncologic Drugs Advisory Committee (ODAC) - Day 2; 2022. Available from: https:\/\/www.youtube.com\/watch?v=cjkgIpaxHlI. Accessed December 27, 2022."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1200\/JCO.20.03433","volume":"39","author":"Fowler","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2020-134783","volume":"136","author":"Gribben","year":"2020","journal-title":"Blood"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.clml.2020.08.022","volume":"21","author":"Phillips","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/14737140.2017.1285702","volume":"17","author":"Greenwell","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.2147\/OTT.S189032","volume":"14","author":"Shah","year":"2021","journal-title":"OncoTargets Ther"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e432","DOI":"10.1016\/j.clml.2020.12.016","volume":"21","author":"Ma","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1080\/10428194.2021.1948038","volume":"62","author":"Wagner-Johnston","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","volume":"18","author":"Zelenetz","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.18.01460","volume":"37","author":"Sharman","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","volume":"22","author":"Matasar","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.1182\/bloodadvances.2021005132","volume":"5","author":"Davids","year":"2021","journal-title":"Blood Adv"},{"key":"ref58","unstructured":"FDA. Commissioner O of the. Ukoniq (Umbralisib): drug safety communication - FDA investigating possible increased risk of death with lymphoma. FDA; 2022. Available from: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/ukoniq-umbralisib-drug-safety-communication-fda-investigating-possible-increased-risk-death-lymphoma. Accessed June 23, 2022."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1182\/blood-2022-160334","volume":"140","author":"Rao","year":"2022","journal-title":"Blood"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/hon.133_2629","volume":"37","author":"Zelenetz","year":"2019","journal-title":"Hematol Oncol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S1470-2045(22)00333-3","volume":"23","author":"Pagel","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["Blood and Lymphatic Cancer: Targets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=87968","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=87968","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T13:55:20Z","timestamp":1678197320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/pi3k-inhibitors-in-nhl-and-cll-an-unfulfilled-promise-peer-reviewed-fulltext-article-BLCTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":61,"URL":"https:\/\/doi.org\/10.2147\/blctt.s309171","relation":{},"ISSN":["1179-9889"],"issn-type":[{"value":"1179-9889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}